Kathleen (Katie) Sicinski
I received my PhD in Chemistry from Tufts University in 2021. My thesis focused on developing novel chemical methods to enhance the metabolic stability of therapeutic peptides in the GLP-1 peptide family, which includes hormones like Ozempic. This work resulted in a start-up company Velum, Inc founded by my PhD advisor Prof. Krishna Kumar. During my PhD, I had the privilege of representing Velum at the Tufts University $100k New Ventures Competition, where we secured 3rd place. After my PhD, I worked as a scientist for a start-up biotech company, PepGen, Inc. At PepGen, I saw the company go from series C fundraising to its initial public offering in 2022 and advanced into clinical trials for the treatment of Duchenne muscular dystrophy. I was responsible for transitioning laboratory operations from Oxford, UK to Boston, MA and discovering new bioconjugation methods for delivery of therapeutic oligonucleotides into target cells. I then moved in 2022 to my current position at California Institute of Technology as a NIH Ruth L. Kirschstein NRSA Postdoctoral Fellow in the lab of Prof. Frances Arnold. In my current position, I utilize the powerful tools of directed evolution for protein engineering and apply machine learning methods to accelerate wet-lab discoveries. This is where I met my current co-founder, Ravi Lal. We have been working together to fast-track the iterative process of protein engineering by incorporating machine learning and high throughput analytical tools to deliver sustainable biocatalysts for the synthesis of molecules.
I am interesting in learning about the financial aspects of starting a company and/or investing in others.